PrEPared to choose: the protocol for an implementation study of the delivery of cabotegravir long-acting injectable pre-exposure prophylaxis (PrEP) as an HIV prevention product option within a real world PrEP choice context in cape town
This is a phase 3B clinical trial registered with the South African Health Products Regulatory Authority (20230904). Ethical approval was granted by the Human Research Ethics Committee (Faculty of Health Sciences, University of Cape Town, 567/2023). It is registered with the South African National Clinical Trial Registry (DOH-27-012024-5189, 26 January 2024) and ClinicalTrials.gov (NCT06807736, retrospectively registered on 4 February 2025).
Authors
- Kgomotso Lebelo (ORCID: https://orcid.org/0000-0003-2282-6375)
- Linda‐Gail Bekker (ORCID: https://orcid.org/0000-0002-0755-4386)
- Francesca Little (ORCID: https://orcid.org/0000-0002-5917-9928)
- Elzette Rousseau (ORCID: https://orcid.org/0000-0002-6487-6736)
- C. Pike
- Dvora Joseph Davey (ORCID: https://orcid.org/0000-0001-6290-9293)
- P. Macdonald (ORCID: https://orcid.org/0009-0003-7925-4782)
- Pakama Mapukata
Institutions
- Desmond Tutu HIV Foundation (ZA)
- University of Cape Town (ZA)
- University of California, Los Angeles (US)
Publication Details
- Journal
- BMC Public Health
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1186/s12889-025-24370-z
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Cape Town